ArticleFrontiers in oncology2026
Selective agonists of the glucocorticoid receptor (SEGRA) as an alternative to glucocorticoids: a pilot study of their effects on normal mouse brain tissue in the context of an acute peripheral inflammatory model
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucocorticoids (GCs) are used to treat multiple pathologies; however, their prolonged use leads to numerous adverse effects. Non-steroidal selective agonists of the glucocorticoid receptor (SEGRAs) have the potential to be a worthy substitute for dexamethasone (DXM). The aim of this study was to compare the effects of SEGRAs and DXM on the cell composition and extracellular matrix of normal brain tissue, with a focus on the acute short-term effects of these drugs. Methods: C57Bl/6 mice (n = 28) received an intraperitoneal injection of SEGRA (CpdA or CpdA-03) or DXM after carrageenan-induced paw edema. After 7.5 h, brain tissue was analyzed for neurons and astrocytes by IHC and Western blotting (anti-NF and anti-GFAP, respectively). Expression of proteoglycan (PG) core proteins and heparan sulfate (HS) metabolism-involved genes was determined by RT-PCR. The glycosaminoglycan (GAG) content was determined by dot blot and Alcian blue staining. Results: All studied drugs possessed similar anti-edema activity but differed in their effects on brain tissue. Unlike DXM, SEGRAs had no effect on neurofilament (NF) content in the mouse brain. Regarding astrocytes, although all drugs increased astrocyte number and outgrowth, only DXM and CpdA, but not CpdA-03, induced the appearance of a minor (44kDa) GFAP isoform associated with neurocognitive impairment. Neither DXM nor CpdA-03 affected the expression of genes coding PG core proteins and HS biosynthetic enzymes, and only CpdA upregulated the expression of syndecan-3, neurocan, aggrecan, and biglycan (2.5- to 3.5-fold). At the same time, all drugs decreased the content of total (1.5- to 2.8-fold) and sulfated (2- to 3-fold) GAGs, with the least effect observed for CpdA-03. Conclusion: Between the two studied SEGRAs, CpdA shows more pronounced effects on the cellular and extracellular components of normal mouse brain tissue compared with DXM. CpdA-03 demonstrated the least effect on brain tissue and may be promising for further development as a less toxic replacement for glucocorticoids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.